• Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of 'platinum-sensitive' ovarian cancer and has been shown to improve progression-free survival (PFS). (cun.es)
  • As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR -mutant advanced non-small cell lung cancer (NSCLC). (ascopost.com)
  • Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults. (nice.org.uk)
  • In this study, we focus on evaluating association between DNA repair polymorphisms of EXO1, RPA1, and prognosis in lung cancer patients whom received platinum-based chemotherapy. (hindawi.com)
  • Rs1776148, rs1047840, and rs5030740 may act as prognosis markers in lung cancer patients with platinum-based chemotherapy. (hindawi.com)
  • And platinum-based chemotherapy still acted as the first-line treatment for lung cancer patients. (hindawi.com)
  • How would you define attempts to improve upon outcomes with platinum-based chemotherapy for patients with newly diagnosed metastatic urothelial cancer? (onclive.com)
  • We did have 2 switch maintenance trials from chemotherapy to a checkpoint inhibitor in patients who had achieved a response or stable disease to platinum-based chemotherapy. (onclive.com)
  • The drug is also approved as a maintenance therapy for patients who have responded to a platinum-based chemotherapy. (fool.com)
  • Several of these drugs were approved as initial therapies ( first-line therapy ) for some people with advanced bladder cancer who, for various health reasons, cannot receive platinum-based chemotherapy. (cancer.gov)
  • Other approvals were for bladder cancer that recurs after platinum-based chemotherapy ( second-line therapy ). (cancer.gov)
  • Platinum-based chemotherapy can be grueling, he continued, and "these patients have had four to six cycles of treatment, and they're pretty beat up. (cancer.gov)
  • Investigators of the multi-center, double-blind phase 3 DUO-E trial assessed the safety and efficacy of durvalumab plus platinum-based chemotherapy followed by maintenance durvalumab on its own or in combination with olaparib for patients with newly diagnosed recurrent or advanced endometrial cancer. (cancernetwork.com)
  • ICIs can prolong overall survival (OS) in patients with aUC after platinum-based chemotherapy (either as switch maintenance or salvage therapy). (urotoday.com)
  • Currently, pembrolizumab, nivolumab, and avelumab are FDA-approved after progression on first line platinum-based chemotherapy, while avelumab is also approved as switch maintenance therapy in patients with response or stable disease after frontline platinum-based therapy. (urotoday.com)
  • Upon progression on platinum-based chemotherapy and ICI, there are other therapeutic options, such as enfortumab vedotin, sacituzumab govitecan, erdafitinib (for patients with FGFR2 or FGFR3 activating mutation or fusion), and even salvage chemotherapy. (urotoday.com)
  • These patients can be presumed to have ovarian carcinoma or primary peritoneal carcinoma and treated with cytoreductive surgery and platinum-based chemotherapy. (medscape.com)
  • Today, treatment consists of maximal surgical removal plus craniospinal radiotherapy and maintenance chemotherapy. (news-medical.net)
  • In limited-stage SCLC, the overall survival rate has been significantly improved by adding dose-hyperfractionated thoracic radiotherapy and prophylactic cranial irradiation to systemic chemotherapy. (ersjournals.com)
  • This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. (ersjournals.com)
  • With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumor-treating fields will be presented. (cancernetwork.com)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • 1. Patients requiring definitive radical radiotherapy to primary tumour site as sole local therapy following discussion by local multidisciplinary team. (who.int)
  • 1. Patients requiring post-operative radiotherapy following discussion by local multidisciplinary team according to multidisciplinary team meeting. (who.int)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Three randomized trials have been performed in patients with ovarian cancer comparing different IP regimens to standard therapy with intravenous agents. (jnccn.org)
  • Co-morbid systemic illnesses such as active infection or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. (mayo.edu)
  • It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. (haematologica.org)
  • Investigators identified greater clinical benefit with durvalumab/olaparib maintenance compared with the other study regimens. (cancernetwork.com)
  • Increasingly, there are promising data emerging for the use of ICIs as part of perioperative regimens in clinical trials, as well as for use early in the metastatic setting, such as the enfortumab vedotin and pembrolizumab combination regimen for cisplatin-ineligible patients. (urotoday.com)
  • These trends are pointing towards a situation where more patients may be treated with ICI-based regimens earlier in their disease course in the near future. (urotoday.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • For more information on chemotherapy regimens, see Ovarian Cancer Treatment Protocols . (medscape.com)
  • Surgery (radiation therapy if the patient is not a surgical candidate), with or without adjuvant chemotherapy based on risk factors, for stages IB and II is generally appropriate. (medscape.com)
  • the benefit of adding adjuvant chemotherapy increases as disease stage increases. (medscape.com)
  • Atezolizumab 840mg IV q2Weeks, 1200 mg IV q3Weeks, or 1680 mg IV q4Weeks for up to 1 year (for completely resected IIB-IIIA or high-risk stage IIA programmed death ligand 1 (PD-L1) ≥1% NSCLC in patients who previously received adjuvant chemotherapy. (medscape.com)
  • 3. Temozolomide (TMZ) - Concomitant TMZ chemotherapy during RT and adjuvant (maintenance) TMZ for 6 cycles has been shown to significantly improve survival (HR 0.63)3. (orlandohealth.com)
  • TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION ]. (rxlist.com)
  • Nivolumab was FDA-approved in August 2021 as adjuvant therapy for patients with high-risk features (based on pathologic stage) after definitive surgery for urothelial cancer. (urotoday.com)
  • Another important question is regarding the efficacy of ICI in aUC patients who received ICI in localized settings (ie pembrolizumab in non-muscle invasive bladder cancer or adjuvant nivolumab in muscle-invasive bladder cancer setting). (urotoday.com)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • Patients who are not candidates for optimal debulking should be considered for neoadjuvant chemotherapy followed by interval debulking surgery and further chemotherapy. (medscape.com)
  • As a result, there is no standardized treatment regimen for these drugs in the context of MM maintenance therapy. (medicalnewstoday.com)
  • Surprisingly, the outcome in this population was similar to that observed in patients who received the full six cycles of the induction regimen. (haematologica.org)
  • About half of the patients who were rechallenged with an ICI-based regimen achieved disease control, and 13% had response to that second ICI treatment. (urotoday.com)
  • The most commonly used chemotherapy regimen was the BFM-95 protocol. (bvsalud.org)
  • Chemotherapy consisted of pemetrexed at 500 mg/m 2 plus either cisplatin at 75 mg/m 2 or carboplatin at AUC 5 every 3 weeks for four cycles. (ascopost.com)
  • We recruited patients aged older than 18 years with unresectable malignant mesothelioma with no evidence of disease progression after at least four cycles of first-line chemotherapy (with platinum and pemetrexed), who had a WHO performance status of 0-2, adequate organ function, and measurable or evaluable disease. (mesothelioma-line.com)
  • This is called maintenance chemotherapy and will be repeated in cycles every 28 days. (childrensoncologygroup.org)
  • Maintenance chemotherapy will continue for up to 10 cycles. (childrensoncologygroup.org)
  • Four maintenance cycles were given beginning 2-3 weeks after surgery. (medscape.com)
  • With chemotherapy for stage IB or II NSCLC, the goal is to complete four cycles. (medscape.com)
  • Patients will be randomized 2:1 to ponatinib 30 mg/d or imatinib 600 mg/d PO with reduced-intensity chemotherapy in induction (Cycles 1-3), consolidation (Cycles 4-9), and maintenance (Cycles 10-20). (confex.com)
  • The reduced-intensity chemotherapy backbone consists of three 28-day cycles of vincristine and dexamethasone for the induction phase, six 28-day cycles of alternating cytarabine (even-numbered cycles) and methotrexate (odd-numbered cycles), and eleven 28-day cycles of vincristine and prednisone for the maintenance phase. (confex.com)
  • After 20 cycles, patients stay on single-agent ponatinib/imatinib. (confex.com)
  • As per protocol, 15 patients (17.8%), who achieved a complete response and undetectable peripheral blood and BM residual disease after four courses of induction, were allowed to stop fludarabine and cyclophosphamide and complete two additional courses of rituximab and continue with maintenance therapy for 18 cycles. (haematologica.org)
  • Patients received placebo once every 3 weeks for 6 cycles followed by placebo maintenance, 1120 mg of durvalumab once every 3 weeks followed by 1500 mg of durvalumab maintenance every 4 weeks plus placebo, or durvalumab followed by maintenance with durvalumab plus 300 mg of olaparib twice a day. (cancernetwork.com)
  • In this final update of the survival analysis, 90% of patients have died. (cun.es)
  • Osimertinib plus chemotherapy significantly improved progression-free survival vs osimertinib alone in patients with EGFR -mutant NSCLC. (ascopost.com)
  • Among 226 patients with central nervous system (CNS) metastases at baseline, median progression-free survival was 24.9 months vs 13.8 months (HR = 0.47, 95% CI = 0.33-0.66). (ascopost.com)
  • Among 331 patients without CNS metastases, median progression-free survival was 27.6 months vs 21.0 months (HR = 0.75, 95% CI = 0.55-1.03). (ascopost.com)
  • At data cutoff (27% data maturity for overall survival), death had occurred in 71 patients in the osimertinib/chemotherapy group vs 78 in the osimertinib monotherapy group (HR = 0.90, 95% CI = 0.65-1.24, P = .52). (ascopost.com)
  • The investigators concluded: "First-line treatment with osimertinib/chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR- mutated advanced NSCLC. (ascopost.com)
  • Interpretation: Switch-maintenance gemcitabine, after first-line chemotherapy, significantly prolonged progression-free survival compared with best supportive care alone, among patients with malignant mesothelioma. (mesothelioma-line.com)
  • Maintenance therapy aims to make this period last as long as possible, and it may improve survival rates for people with MM. (medicalnewstoday.com)
  • Maintenance treatment with eprenetapopt, a novel drug, plus the chemotherapy Vidaza (azacitidine) following allogeneic hematopoietic stem cell transplantation was associated with improved survival outcomes in a group of patients with TP53-mutant, high-risk acute myeloid leukemia and myelodysplastic syndromes, according to new study findings. (curetoday.com)
  • They conducted a phase 2, multicenter trial to analyze if post-transplant eprenetapopt plus Vidaza improved relapse-free survival (which is the length of time following completion of primary treatment that a patient survives without signs or symptoms of that cancer). (curetoday.com)
  • Ganetespib, a highly potent, small-molecule Heatshock protein 90 inhibitor, has potential efficacy in malignant pleural mesothelioma (MPM) via activity on critical survival pathways and known synergies with antifolates and platinum chemotherapy. (aacrjournals.org)
  • Despite the advances in diagnosis method that have been used to control the mortality, most patients still have a poor prognosis and high death rates, with an overall 5-year survival rate of 10% to 15% [ 3 ]. (hindawi.com)
  • Adolescent patients all bear an intermediate to high prognostic risk, leading to poor patient survival and disability. (news-medical.net)
  • It therefore aims to improve PFS, translating into a higher survival rate and clinically relevant functional improvements for the affected patients. (news-medical.net)
  • Maintenance therapy with IP cisplatin also failed to improve survival in patients who obtained complete remission after intravenous chemotherapy. (jnccn.org)
  • 6. Lomustine-TMZ as maintenance therapy might improve survival in newly diagnosed patients compared to maintenance TMZ alone, as suggested by an open-label phase 3 trial in 141 patients, which demonstrated a HR of 0.6 (95% CI 0.35-1.03, p=0.0492) for the combined treatment9. (orlandohealth.com)
  • To determine if TTFields treatment at 200 kHz to the brain concomitantly with RT and TMZ in the treatment of GBM patients prolongs the overall survival of patients, compared to RT and TMZ treatments followed by TTFields and maintenance TMZ. (orlandohealth.com)
  • If left untreated, patients with SCLC rarely survive longer than a few months 5 , but chemotherapy dramatically prolongs survival compared to the best supportive care 6 . (ersjournals.com)
  • Patients who received avelumab as maintenance therapy had "the longest overall survival ever documented" in a clinical trial for patients with metastatic bladder cancer, said Elizabeth Plimack, M.D., head of bladder cancer research at Fox Chase Cancer Center, who was not involved with the study, speaking at the ASCO meeting. (cancer.gov)
  • After a median followup of 6.30 years, the median overall survival (OS) and PFS had not been reached in patients with either undetectable or detectable residual disease in the BM, who had achieved a complete response at the time of starting maintenance therapy. (haematologica.org)
  • Durvalumab (Imfinzi) plus chemotherapy followed by maintenance with durvalumab alone or in combination with olaparib (Lynparza) demonstrated statistically significant improvements in progression-free survival (PFS) compared with chemotherapy alone in patients with newly diagnosed recurrent or advanced endometrial cancer, according to a press release on data from the phase 3 DUO-E trial (NCT04269200). (cancernetwork.com)
  • Additionally, there was a favorable overall survival (OS) trend for durvalumab with or without olaparib as maintenance, although these data were immature at the time of this analysis. (cancernetwork.com)
  • In the initial clinical trial, hypomethylating agents were studied in patients with high-risk myelodysplastic syndrome, where it showed that it improved hematologic parameters, reduced risk of transformation to acute myeloid leukemia, and improved the overall survival. (ajmc.com)
  • In recent years, several studies have looked at different approaches, [such as] combinations of chemotherapy plus immunotherapy. (onclive.com)
  • Our program was created for people who are going through IV chemotherapy, or intensive immunotherapy treatment for certain types of cancer. (chemoangels.com)
  • For most people with advanced bladder cancer , starting immunotherapy shortly after initial treatment with chemotherapy is better than taking an extended break from cancer treatment, according to results from a new study. (cancer.gov)
  • These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further,' according to an expert from The University of Texas MD Anderson Cancer Center. (cancernetwork.com)
  • These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further," lead investigator Shannon N. Westin, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, said in the press release. (cancernetwork.com)
  • He was receiving maintenance treatment with intravenous (IV) rituximab every 3 months and IV immunoglobulin for hypogammaglobulinemia. (cdc.gov)
  • If patients have fever and neutropenia, admission is required for intravenous antibiotics and monitoring. (medscape.com)
  • Intravenous catheter removal is recommended for non-neutropenic patients and can be considered for neutropenic patients. (cdc.gov)
  • We offer patients who have high-risk disease IV [intravenous] azacitidine, a 7-day treatment, and then there's IV decitabine, which is given over 5 days. (ajmc.com)
  • Patients remain on study treatment until they complete study, relapse from complete remission (CR), have progressive disease, have unacceptable toxicity, withdraw consent, proceed to hematopoietic stem cell transplant (HSCT), or sponsor terminates study. (confex.com)
  • This has become a viable and effective option for patients with early-stage NSCLC who are not surgical candidates and in those with significant co-morbidities. (medscape.com)
  • This has important clinical implications as, in contrast to advanced-stage NSCLC, chemotherapy can also be offered to patients with SCLC and a poor or bad performance status (World Health Organization performance status of 2-3), since a rapid amelioration of the patient's symptoms and general condition can be expected together with an improved outcome 7 . (ersjournals.com)
  • Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor ( EGFR ) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. (rxlist.com)
  • TAGRISSO is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION ]. (rxlist.com)
  • TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutationpositive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy [see DOSAGE AND ADMINISTRATION ]. (rxlist.com)
  • Background: Almost all patients with malignant mesothelioma eventually have disease progression after first-line therapy. (mesothelioma-line.com)
  • We aimed to assess the efficacy and safety of switch-maintenance gemcitabine in patients with malignant mesothelioma without disease progression after first-line chemotherapy. (mesothelioma-line.com)
  • Two patient deaths were reported during the study period - one that was associated with a side effect not related to study treatment and one attributed to disease progression more than 30 days after study treatment completion. (curetoday.com)
  • For instance, what is the efficacy of ICI rechallenge in patients who have progression after avelumab switch maintenance which is now the standard of care? (urotoday.com)
  • Expression of mutations in tumor gene p53 may be associated with both progression and resistance to chemotherapy. (msdmanuals.com)
  • This trial was designed such that patients with a response or stable disease after gemcitabine plus cisplatin or gemcitabine plus carboplatin were randomized to avelumab [Bavencio], a PD-L1 inhibitor plus best supportive care vs best supportive care alone. (onclive.com)
  • Fig. 1: Differences in GI, HRD and CHTP across AA and EA patients with lung cancer from the NCI-MD and TCGA cohorts. (nature.com)
  • Fig. 4: Landscape of SCNA of lung cancer drivers AA and EA patients in the NCI-MD cohort. (nature.com)
  • Fig. 5: Landscape of GI, HRD and CHTP across AA and EA patients with lung cancer in the TCGA cohort. (nature.com)
  • Fig. 6: Landscape of germline HRD across AA and EA patients in the pan-cancer and LUSC TCGA cohort. (nature.com)
  • There was an average BSA of 1.73 m2 for 3,000 cancer patients from 1990 to 1998 in a European Organisation for Research and Treatment of Cancer (EORTC) database. (wikipedia.org)
  • During 2005 there was an average BSA of 1.79 m2 for 3,613 adult cancer patients in the UK. (wikipedia.org)
  • Of note, an allogeneic hematopoietic stem cell transplant is a procedure where a patient with cancer receives healthy blood-forming stem cells from a donor to replace their own stem cells that have been damaged by other cancer treatments such as radiation or chemotherapy. (curetoday.com)
  • 593 lung cancer patients were recruited in this study. (hindawi.com)
  • Besides clinical factors of age, sex, smoking stage, histology, and grade, many genetic polymorphisms also were considered correlation with prognosis in cancer patients. (hindawi.com)
  • Thus, considering poor prognosis of lung cancer patients, it is crucial to find prognosis markers to develop predictive therapeutic methods. (hindawi.com)
  • found that high expression level of the EXO1 is associated with poor OS in breast and prostate cancer patients [ 26 , 27 ]. (hindawi.com)
  • In a Phase 2 trial, patients with a specific type of cancer receive a new treatment using a dose that was found to be safe in a Phase 1 trial. (childrensoncologygroup.org)
  • Patients are checked for side effects of the treatment and to see whether the cancer shrinks or goes away. (childrensoncologygroup.org)
  • Gateway for Cancer Research℠ awards grant to the EORTC 1634- Brain Tumour Group (BTG) academic trial in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I). (news-medical.net)
  • EORTC is proud to count Gateway for Cancer Research as their partner in tackling unmet patient-centered needs in cancer clinical research. (news-medical.net)
  • Gateway for Cancer Research and EORTC are deeply committed to advancing research that ultimately changes the standard of care for cancer patients worldwide. (news-medical.net)
  • With the freedom of taking a pill, I don't even feel like a cancer patient anymore! (lymphoma.org)
  • For the first year as a WM patient, I woke up every morning horrified that I had cancer. (lymphoma.org)
  • My brother Mike, a 14-year cancer survivor, called me before and after literally all 50 of my chemotherapy infusions as he understood too well how challenging treatment can be. (lymphoma.org)
  • Intraperitoneal (IP) chemotherapy in ovarian cancer has been studied since 1978. (jnccn.org)
  • For patients undergoing chemotherapy and surgery for esophagogastric cancer, maintenance of fitness is paramount. (nih.gov)
  • This parallel-arm randomized controlled trial assigned patients with locally advanced esophagogastric cancer to receive prehabilitation or usual care. (nih.gov)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • With chemotherapy , we treat the cancer cells in the blood and also the bone marrow. (mdanderson.org)
  • Baduanjin Qigong exercise can relieve CRF in patients with colorectal cancer undergoing chemotherapy and can improve their physical activity level and their quality of sleep. (longevity-center.com)
  • We evaluated the treatment patterns and outcome of patients receiving ET for EOC in the Southeast medical region in Sweden.Method: Patients were identified through the population-based Southeast Quality Registry for gynaecological cancer. (diva-portal.org)
  • Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met. (onclive.com)
  • Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma (RCC), and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met, explained Petros Grivas, MD, PhD, in an interview with OncLive ® during an Institutional Perspectives in Cancer webinar on genitourinary malignancies. (onclive.com)
  • The event covered the effects of recent and emerging research on current standards of care in the treatment of patients with metastatic urothelial cancer and RCC. (onclive.com)
  • The field is evolving very fast, and there have been attempts to improve upon chemotherapy alone in the frontline setting for patients with advanced urothelial cancer. (onclive.com)
  • Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. (ersjournals.com)
  • Small cell lung cancer (SCLC) is an aggressive malignant disease, with the majority of patients presenting with distant metastasis at diagnosis. (ersjournals.com)
  • The International Association for the Study of Lung Cancer defines limited-stage SCLC (LS-SCLC) as: "disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative" 2 . (ersjournals.com)
  • Patients with this cancer type face significant morbidity and mortality, with over 13,000 deaths per year in the United States. (cancernetwork.com)
  • Advanced lung cancer usually implies that a patient has either stage IIIB or stage IV lung cancer. (medpagetoday.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • Rubraca is currently approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer with mutations in BRCA genes who have been treated with two or more chemotherapies. (fool.com)
  • PET-CT scan of a patient with bladder cancer that has spread throughout the abdomen. (cancer.gov)
  • On July 1, 2020, the Food and Drug Administration (FDA) approved avelumab (Bavencio) for people with advanced bladder cancer that has shrunk or stopped growing after chemotherapy using a platinum-based drug. (cancer.gov)
  • Although most bladder cancers stop growing, shrink, or even disappear in response to chemotherapy that uses a platinum-based drug (such as cisplatin), the cancer almost always returns rapidly, sometimes within just a few weeks or months, and grows aggressively. (cancer.gov)
  • Patients are left in what can feel like a no-win situation, explained Arjun Balar, M.D., director of Genitourinary Medical Oncology at NYU Langone Health's Perlmutter Cancer Center, who was not involved with the study. (cancer.gov)
  • Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent. (cancernetwork.com)
  • Surgery is often the initial treatment of choice for ovarian cancer, provided patients are medically fit. (medscape.com)
  • As an oncologist and lead investigator of the CDC's Preventing Infections in Cancer Patients program, I am proud to be a part of a program that educates and empowers people with cancer. (cdc.gov)
  • Chemotherapy drugs kill cancer cells as well as healthy white blood cells. (cdc.gov)
  • Preventing Infections in Cancer Patients is a comprehensive program focused on providing information, action steps, and tools to help reduce the risk of developing potentially life-threatening infections during chemotherapy treatment. (cdc.gov)
  • The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors. (curetoday.com)
  • Glucocorticoid dosing is also expressed in terms of BSA for calculating maintenance doses or to compare high dose use with maintenance requirement. (wikipedia.org)
  • We conducted a dose-escalation study to identify the maximum tolerated dose (MTD) of ganetespib in patients with chemotherapy-naïve MPM. (aacrjournals.org)
  • The study will prospectively investigate molecular subtypes in an adult population, addressing the area of better characterization of cancers through biomarkers, and will implement a dose reduction of radio-chemotherapy in its experimental arms, focusing on treatment de-escalation. (news-medical.net)
  • Blood chemistries: Monitoring blood chemistries, including monitoring with renal and liver function tests, is important for patients receiving parenteral nutrition or for those who have a history of organ toxicity (especially if nephrotoxic or hepatotoxic antibiotics or other drugs are continued). (medscape.com)
  • In addition, by decreasing toxicity in its risk-adapted setting, the study will help to decrease short- and long-term toxicity burden and thereby help to re-integrate affected patients in their social and professional lives. (news-medical.net)
  • However, the risk of toxicity is greater in this group than in patients with good performance status. (ersjournals.com)
  • Importantly, of the 4 patients who stopped 1st ICI due to immune-related toxicity, none had the same toxicity with 2nd ICI. (urotoday.com)
  • The orthopedic surgeon is often the first subspecialist to evaluate the patient with a suspected bone tumor. (medscape.com)
  • There is therefore an unmet medical and scientific need to help treat adolescent and adult patients burdened by this rare brain tumor. (news-medical.net)
  • Surgical resection - Treatment of patients with GBM usually consists of tumor resection (to the extent safely feasible) or diagnostic biopsy. (orlandohealth.com)
  • Poorer documentation and irregular tumor response assessment were observed for endocrine treatment compared to chemotherapy. (diva-portal.org)
  • We are proud to partner with EORTC to fund this promising clinical trial, and we are confident that our collaboration will truly accelerate progress for the patients we are privileged to serve. (news-medical.net)
  • 5. TTFields - Large-scale, phase III clinical studies have validated the safety and efficacy of TTFields in patients with recurrent and newly diagnosed glioblastoma6,8. (orlandohealth.com)
  • This will potentially be of benefit in opening up appropriate clinical trial opportunities for this subset of patients in the future. (cancernetwork.com)
  • After clinical evaluation, 74 patients went into rituximab maintenance and the primary endpoint was assessed in the final analysis at 3 years of follow-up. (haematologica.org)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • First-line therapy in ES-SCLC currently consists of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. (ersjournals.com)
  • The first-line treatment of ES-SCLC currently consists of chemotherapy with a platinum derivative and etoposide, a combination that was first reported to be effective in the treatment of SCLC in 1985 8 , 9 . (ersjournals.com)
  • While patients given the right combination of drugs lose their infectivity in a few weeks (probably most often in less than two weeks), treatment must of course be continued much longer and regularly in order to ensure the maintenance of conversion and the absence of relapse. (nih.gov)
  • Grade 3-4 adverse events occurred in 33 (52%) of 64 patients in the gemcitabine group and in ten (16%) of 62 patients in the supportive care group. (mesothelioma-line.com)
  • One patient (2%) in the gemcitabine group died, due to a treatment-related infection. (mesothelioma-line.com)
  • The outcomes of patients on this study will be compared to other patients with clinically and molecularly similar HGG treated with temozolomide alone. (childrensoncologygroup.org)
  • A Phase 2 study of ponatinib with chemotherapy in newly diagnosed Ph+ ALL reported improved long-term outcomes versus a second-generation tyrosine kinase inhibitor (TKI) (Sasaki 2016). (confex.com)
  • These combinations could provide physicians with new treatment approaches to improve outcomes for patients. (cancernetwork.com)
  • There have not been much data suggesting whether ICI rechallenge provides meaningful outcomes for patients previously treated with ICI. (urotoday.com)
  • As stand-alone maintenance therapies, there is limited evidence to confirm that proteasome inhibitors work. (medicalnewstoday.com)
  • However, some MM maintenance therapies are less likely to cause side effects. (medicalnewstoday.com)
  • In view of novel combination therapies, it will use a targeted therapy in combination with radio-chemotherapy in a randomized setting, based on evaluation of the genetic subtype of medulloblastoma, and will therefore be personalized. (news-medical.net)
  • Patients with lymphoproliferative disorders being observed (i.e., never treated) or those on rituximab (or equivalent) maintenance or chronic oral therapies such as BTK inhibitors, venetoclax, tazemetostat, or corticosteroids are also eligible. (mayo.edu)
  • A lot of times, these patients were used to IV therapies, and the same question came up with us: "Is there any oral agent I can take? (ajmc.com)
  • In the open-label international trial, 557 patients with exon 19 deletions or L858R mutations who had received no prior treatment for advanced disease were randomly assigned between June 2020 and December 2021 to receive osimertinib at 80 mg once daily with the investigator's choice of chemotherapy (n = 279) or osimertinib at 80 mg once daily alone. (ascopost.com)
  • Patients in the osimertinib/chemotherapy group also received pemetrexed maintenance. (ascopost.com)
  • Overall, 64% of patents in the osimertinib/chemotherapy group and 63% in the osimertinib-alone group were Asian. (ascopost.com)
  • Grade ≥ 3 adverse events occurred in 64% of the osimertinib/chemotherapy group vs 27% of the osimertinib monotherapy group (no grade 4 events). (ascopost.com)
  • Adverse events led to discontinuation of osimertinib in 11% of the osimertinib/chemotherapy group and in 6% of the osimertinib monotherapy group. (ascopost.com)
  • Fatal adverse events considered possibly related to study treatment were reported in five patients in the osimertinib/chemotherapy group and one patient in the osimertinib group. (ascopost.com)
  • It will unify the pediatric and the adult neuro-oncology trial world and be the first trial worldwide that includes pediatric and adult patients in a prospective setting, also addressing patient feedback. (news-medical.net)
  • A transversal type study was performed preparations for a long time in various cultures to involving 94 pediatric patients, aged from 6 to 15 enhance the sensory qualities in food. (bvsalud.org)
  • For patients with no disease visible outside the ovaries, adequate surgical staging is essential because the incidence of microscopic metastases is significant. (medscape.com)
  • As a patient who is also a certified infection preventionist, I am going to ask my oncologist to hire me at a very low wage to teach patients about hand sanitation, preventing surgical site infections,line infections,etc. (cdc.gov)
  • The PhALLCON trial (NCT03589326) is a randomized study that compares efficacy and safety of first-line ponatinib versus imatinib with reduced-intensity chemotherapy. (confex.com)
  • Moreover, results from prior studies have shown the combination to be safe and effective in patients with other forms of blood cancers. (curetoday.com)
  • In this study, patients with a HGG that has specific molecular features (wild-type for H3-K27, IDH and BRAF) will receive experimental therapy of veliparib (given by mouth) during radiation therapy, followed by veliparib in combination with temozolomide. (childrensoncologygroup.org)
  • For high-risk myelodysplastic syndrome, we're able to offer the oral decitabine-cedazuridine combination for these patients. (ajmc.com)
  • The PFS benefit was also significant regardless of PD-L1 expression, favoring avelumab, and the benefit was seen across the board in different subsets of patients based on the treatment by subgroup interaction test that we did. (onclive.com)
  • The approval is for the use of avelumab as maintenance therapy for advanced disease that has not spread ( locally advanced ) or disease that has spread beyond the bladder ( metastatic ). (cancer.gov)
  • This study helps fill this knowledge gap, investigating a multi-institutional retrospective cohort of patients with aUC who received ICI rechallenge following prior ICI treatment. (urotoday.com)
  • In this retrospective cohort including patients across multiple sites in the US and Europe, we identified and described the characteristics and treatment response of 25 patients with aUC who received ICI-based therapy with two distinct ICI-based courses during their treatment. (urotoday.com)
  • Previous studies have investigated maintenance therapy, but none has shown a great effect. (mesothelioma-line.com)
  • Maintenance therapy for multiple myeloma (MM) occurs after successful treatment. (medicalnewstoday.com)
  • This article looks at maintenance therapy, a type of treatment doctors can use for MM. (medicalnewstoday.com)
  • It will detail the goals of maintenance therapy and the main types. (medicalnewstoday.com)
  • It also looks at how long maintenance therapy lasts and its impact on a person's quality of life. (medicalnewstoday.com)
  • As long as maintenance therapy is effective, individuals with MM will not need these treatments again. (medicalnewstoday.com)
  • However, if maintenance therapy stops working, they may need further treatment using these options. (medicalnewstoday.com)
  • Maintenance therapy can take various forms, but it always involves pharmaceuticals. (medicalnewstoday.com)
  • A 2021 review discusses the main ways doctors use maintenance therapy for MM. (medicalnewstoday.com)
  • How long does maintenance therapy last? (medicalnewstoday.com)
  • Maintenance therapy is a long-term treatment option. (medicalnewstoday.com)
  • Scientists have studied the safety and effectiveness of MM maintenance therapy for periods lasting 1-3 years . (medicalnewstoday.com)
  • In this way, a person could continue to receive MM maintenance therapy for several years. (medicalnewstoday.com)
  • Maintenance therapy for MM can have adverse effects. (medicalnewstoday.com)
  • As a result, investigators aimed to see if maintenance therapy with eprenetapopt and Vidaza would induce similar results in this high-risk patient population. (curetoday.com)
  • Four weeks after completion of radiation therapy, patients will start veliparib twice a day for 5 days AND temozolomide by mouth once a day for 5 days. (childrensoncologygroup.org)
  • Because the patient was improving, IV ceftriaxone was maintained for 18 days, and he was discharged 5 days after the beginning of efficient antimicrobial drug therapy. (cdc.gov)
  • Long-term follow-up: Five years of longer after patients finish therapy, they are considered long-term survivors. (medscape.com)
  • Clotrimazole: Prophylactic therapy for thrush may be discontinued when chemotherapy has been completed. (medscape.com)
  • He extended my therapy for another year of maintenance. (lymphoma.org)
  • There was a signal that maintenance therapy might be the way to go but [that trial] did not change practice because the OS was not prolonged. (onclive.com)
  • As a class, NSCLCs are relatively insensitive to chemotherapy and radiation therapy compared with SCLC. (medpagetoday.com)
  • Bone marrow (BM) MRD analysis was performed after the last planned induction course and every 6 months in cases with detectable residual disease during the 36 months of maintenance therapy. (haematologica.org)
  • Thirty-seven patients (44%) did not have detectable residual disease in the BM prior to maintenance therapy. (haematologica.org)
  • Interestingly, 29 patients with detectable residual disease in the BM after induction no longer had detectable disease in the BM following maintenance therapy. (haematologica.org)
  • For most adult patients with candidemia, an echinocandin is recommended as initial therapy, with transition to fluconazole once the infecting species and antifungal susceptibility are known and blood cultures have cleared. (cdc.gov)
  • Fluconazole is an acceptable alternative to an echinocandin as initial therapy in selected patients, including those who are not critically ill and who are considered unlikely to have a fluconazole-resistant Candida infection. (cdc.gov)
  • Having treated patients with myelodysplastic syndrome for years, one of the frequently asked questions by my patients was: "Do we have any oral therapy? (ajmc.com)
  • Based on our results, rechallenge with ICI-based therapy in aUC seems feasible and may possibly help a subset of patients, but further data are needed to select patients for this approach optimally. (urotoday.com)
  • Currently, maintenance strategies (which are used to reduce the risk for disease recurrence) are not standard of care in allogeneic (hematopoietic stem cell transplant) for (acute myeloid leukemia and myelodysplastic syndromes)," the study authors wrote. (curetoday.com)
  • Monitoring for recurrence: After completing chemotherapy, patients should continue to undergo regular blood workup and radiographic scanning on an outpatient basis, with the frequency decreasing over time. (medscape.com)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • Pembrolizumab is also FDA-approved in the first line setting for platinum-ineligible patients, as well as for patients with BCG-unresponsive carcinoma in situ for patients who decline or cannot undergo radical cystectomy. (urotoday.com)
  • In this study, we analyzed the outcome of 84 patients at 3 years of follow-up after first-line treatment with fludarabine, cyclophosphamide and rituximab (FCR) induction followed by 36 months of rituximab maintenance thearpy. (haematologica.org)
  • Interestingly, univariate analysis showed that after rituximab maintenance OS was not affected by IGHV status (mutated vs . unmutated OS: 85.7% alive at 7.2 years vs . 79.6% alive at 7.3 years, respectively). (haematologica.org)
  • These data show that, compared to historic controls, patients treated with FCR followed by rituximab maintenance have high-quality responses with fewer relapses and improved OS. (haematologica.org)
  • Cisplatin-based chemotherapy has produced great results. (onclive.com)
  • Conclusions: Oral abnormalities were common in children receiving chemotherapy and mucositis was the most prevalent manifestation. (bvsalud.org)
  • Of the 55 patients who received a transplant, 33 patients (14 with acute myeloid leukemia and 19 with myelodysplastic syndromes) received maintenance treatment with eprenetapopt and Vidaza. (curetoday.com)
  • B19 has also been associated with fetal death (both spontaneous abortions and stillbirths), acute arthralgias and arthritis, and chronic anemia in immunodeficient patients (5-14). (cdc.gov)
  • However, patients with acute leukemias typically bleed easily, like when brushing their teeth. (mdanderson.org)
  • Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. (bvsalud.org)
  • The trial will enroll ~230-320 patients (≥18 years) with newly diagnosed Ph+ or BCR-ABL1-positive ALL (p190/p210 transcript type) and Eastern Cooperative Oncology Group status ≤2. (confex.com)
  • Patients 18 years and older with histologically confirmed epithelial endometrial carcinoma and newly diagnosed stage III or IV disease or recurrent disease were eligible for enrollment on the trial. (cancernetwork.com)
  • The future reduction of transmission will essentially depend on the maintenance of an adequate system ensuring the early diagnosis and correct treatment of cases, which will inevitably continue to appear among the already infected portion of the population. (nih.gov)
  • One week after my diagnosis, on my 30th wedding anniversary, I started chemotherapy which lasted for 18 months and consisted of more than 50 infusions. (lymphoma.org)
  • At the time of diagnosis, 16% of patients have localized disease, 22% regional (spread to regional lymph nodes), and 57% have distant/metastasized disease. (medpagetoday.com)
  • Recently, prophylactic cranial irradiation (PCI) has been shown to improve outcome in patients with ES-SCLC 4 , but only small advances have been made otherwise. (ersjournals.com)
  • Chlorhexidine mouth rinse: Prophylaxis against gingivitis and other mouth infections may be discontinued when chemotherapy is completed. (medscape.com)
  • Eleven years earlier, diffuse large B-cell lymphoma had been diagnosed, and he had undergone 7 chemotherapy courses. (cdc.gov)
  • Phase 2 trials are offered to patients whose disease has not responded to standard types of treatments or to patients whose disease doesn't have a standard treatment. (childrensoncologygroup.org)
  • People who have a high risk of the disease returning may be given chemotherapy drugs . (healthline.com)
  • Since its discovery, B19 has been shown to be the causative agent of erythema infectiosum (EI) (also known as fifth disease) and is the primary etiologic agent of TAC in patients with chronic hemolytic anemias (2-4). (cdc.gov)
  • B19 is the primary etiologic agent causing TAC in patients with chronic hemolytic anemias (e.g., sickle cell disease, hemoglobin SC disease, hereditary spherocytosis, alpha-thalassemia, and autoimmune hemolytic anemia) (22,23). (cdc.gov)
  • The study also implements effective interventions that enable symptom management during and after treatment and empower patients to better handle their disease and become actively involved in their care decisions. (news-medical.net)
  • Care given to improve the quality of life of patients who have a serious or life-threatening disease. (cancer.gov)
  • Among 12 patients re-treated with the same ICI class, only 3 (25%) had progressive disease as best response at the time of rechallenge. (urotoday.com)
  • Surgery for patients with stage IV disease should be individualized, particularly when disease is in the liver and above the diaphragm. (medscape.com)
  • Patients who are in stage IV because of small-volume disease in the liver, abdominal wall, or lung should undergo cytoreductive surgery if medically fit. (medscape.com)
  • median follow-up was 36·5 months (95% CI 34·2 to not reached), and one patient in the supportive care group withdrew consent. (mesothelioma-line.com)
  • Median time from ET to subsequent chemotherapy was 5 months (range 0-79). (diva-portal.org)
  • Nevertheless, there have been several important critiques of the use of BSA in determining the dosage of medications with a narrow therapeutic index, such as chemotherapy. (wikipedia.org)
  • The impact of chemotherapy is reflected by a two-to-three-fold increase in the speed of decline of the risk of infection, a decline which had started before the introduction of the drugs. (nih.gov)
  • In addition, interim guidelines are presented for preventing B19 infection, managing persons exposed to persons with B19 infection, and managing patients infected with B19. (cdc.gov)
  • It will be the first prospective randomized trial in post-pubertal and adult patients with medulloblastoma. (news-medical.net)
  • Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis-B viral replication (presence of DNA of hepatitis-B virus (HBV-DNA) and hepatitis-B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and / or fibrosis. (europa.eu)
  • As SCLC is a very chemosensitive tumour, rapid responses, with symptomatic improvement, are often seen with chemotherapy. (ersjournals.com)
  • Patients with SCLC who do not fit this definition are considered to have extensive-stage SCLC (ES-SCLC). (ersjournals.com)
  • Squamous cell carcinomas, which are less common and usually occur in patients with parasitic bladder infestation or chronic mucosal irritation. (msdmanuals.com)
  • 40% of patients, tumors recur at the same or another site in the bladder, particularly if tumors are large or poorly differentiated or if several tumors are present. (msdmanuals.com)
  • This stresses the importance of providing means to ensure the taking of the drugs by all patients. (nih.gov)
  • These were collected in areas where the staff handled chemotherapy drugs, such as the oncology department. (cdc.gov)